NASDAQ: GMDAGamida Cell Ltd Stock
$1.96-0.02 (-1.01%)
Updated May 26, 2023
GMDA Price
$1.96
Fair Value Price
$2.97
Market Cap
$206.95M
52 Week Low
$0.56
52 Week High
$3.66
P/E
-1.69x
P/B
-13.47x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$80.11M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-7.84
Operating Cash Flow
-$67M
Beta
0.71
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GMDA Overview
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GMDA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GMDA ($1.96) is undervalued by 34.07% relative to our estimate of its Fair Value price of $2.97 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
GMDA ($1.96) is significantly undervalued by 34.07% relative to our estimate of its Fair Value price of $2.97 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
GMDA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GMDA due diligence checks available for Premium users.
Be the first to know about important GMDA news, forecast changes, insider trades & much more!
GMDA News
Valuation
GMDA fair value
Fair Value of GMDA stock based on Discounted Cash Flow (DCF)
Price
$1.96
Fair Value
$2.97
Undervalued by
34.07%
GMDA ($1.96) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GMDA ($1.96) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GMDA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GMDA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.69x
Industry
11.86x
Market
54.23x
GMDA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-13.47x
Industry
5.18x
GMDA's financial health
Profit margin
Revenue
$0.0
Net Income
-$21.0M
Profit Margin
0%
GMDA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$105.1M
Liabilities
$120.5M
Debt to equity
-7.84
GMDA's short-term assets ($48.17M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GMDA's long-term liabilities ($98.23M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GMDA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GMDA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$22.3M
Investing
-$827.0k
Financing
$5.2M
GMDA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GMDA vs Biotech Stocks
Gamida Cell Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.